VivoSeq
Neurology

Brain Injury

206

Pipeline Programs↗

47

Active Trials↗

72

Companies Involved↗

Brain Injury is a highly competitive landscape with 206 programs across 72 companies. The most active players are Pinteon Therapeutics, Inc, Teva, Triax. 42 therapies are approved with 36 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

81/100

Pipeline Velocity

43/100

Mech. Concentration

4/100

Completion Rate

70/100

Attrition Rate

19/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

P

Pinteon Therapeutics, Inc

2 programs

Phase 1Teva logo

Teva

1 program

Phase 1T

Triax

1 program

Phase 1Bayer logo

Bayer

1 program

Phase 1C

Cumberland Pharmaceuticals

1 program

Phase 1J

Jiangsu Topcel-KH Pharmaceutical Co., Ltd.

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical25

Ketamine Hydrochloride

Boehringer Ingelheim

Modafinil

Nuvo Research GmbH

Cerebrolysin

Ever Neuro Pharma GmbH

Simvastatin

Organon and Co

Tongrentang Angong Niuhuang Wan

Huaqiu Zhang

Phase 129

Fosaprepitant

Merck & Co.

Minocycline

Triax

Metformin

EMD Serono

Glutamine

Sanofi

Enoxaparin

Sanofi

Phase 274

Norepinephrine

General Hospital of Ningxia Medical University

Acetaminophen

Kenvue Brands

Darbepoetin Alfa

Amgen

Glyburide

Pfizer

Epoetin Beta

Roche

Phase 336

Onabotulinumtoxina

Vitae Pharmaceuticals Inc., an Allergan affiliate

Xenon

Nobilis Therapeutics Inc.

Citicoline

University of Texas Southwestern Medical Center

Armodafinil

Nuvo Research GmbH

Tranexamic Acid

Amring

Approved42

Gabapentin

Viatris Specialty LLC

Baclofen

Novartis

Nitric Oxide

Mallinckrodt

Baricitinib

Eli Lilly

Dobutamine

Eli Lilly

Analysis

Modality Breakdown

95%

Small molecule

221 of 232 classified programs — the dominant modality here.

5%ALL OTHERSCell therapy83%Monoclonal antibody1<1%Protein / enzyme1<1%Peptide1<1%

Small molecule leads; the ring shows all 232 classified programs, each share of the total. Modality classified for 100% of 246 pipeline programs.

Analysis

Trial Status

263

clinical trials

Completed120 · 46%
Unknown status43 · 16%
Terminated33 · 13%
Recruiting26 · 10%
Withdrawn16 · 6%
Not yet recruiting14 · 5%
Other11 · 4%

Clinical Trials

Trial Activity

263 trials

An Gong Niuhuang Wan Promotes the Postoperative Neurological Function Recovery of Patients With Traumatic Brain Injury
Recruiting·—·N/A·NCT07074938·60 enrolled
Saline Versus Balanced Crystalloid in Traumatic Brain Injury
Recruiting·UUniversity of Louisville·Phase 3·NCT06953674·600 enrolled
Precision Biomarkers to Detect Brain Injury in Active-Duty United States Special Operations Forces With Repeated Blast Exposure
Recruiting·MMassachusetts General Hospital·Phase 2·NCT07131475·100 enrolled
The Anaesthetic Ketamine as Treatment for Patients With Severe Acute Brain Injury
Recruiting·—·Phase 4·NCT05095857·400 enrolled
Hyperpolarized 13C-pyruvate Metabolic MRI With Traumatic Brain Injury
Recruiting·UUniversity of Maryland, Baltimore·Phase 1·NCT06103201·15 enrolled
Buspirone and Melatonin for Depression Following Traumatic Brain Injury
Recruiting·MMassachusetts General Hospital·Phase 4·NCT04400266·10 enrolled
PRophylaxis Against Early VENTilator-associated Infections in Acute Brain Injury
Recruiting·TThe George Institute·Phase 3·NCT06819592·3,300 enrolled
Hyperbaric Oxygen Treatment for Veterans With Traumatic Brain Injury
Recruiting·UUniversity of South Florida·Phase 3·NCT06581003·420 enrolled
Ketamine in Severe Traumatic Brain Injury
Recruiting·UUniversity of Texas Southwestern Medical Center·Phase 1·NCT06062628·10 enrolled
Efficacy of Nucleo CMP Forte in Traumatic Brain Injury in Pediatrics
Recruiting·—·Phase 3·NCT04499755·100 enrolled
Quetiapine to Reduce Post Concussive Syndrome After Mild Traumatic Brain Injury (mTBI)
Recruiting·FFoundation for Advancing Veterans' Health Research·Phase 3·NCT06333990·146 enrolled
Mesenchymal Stromal Cells for Traumatic Brain Injury
Recruiting·FFondazione IRCCS San Gerardo dei Tintori·Phase 2·NCT06163833·78 enrolled
Ketamine in Acute Brain Injury Patients.
Recruiting·—·Phase 4·NCT05097261·100 enrolled
Tranexamic Acid in Traumatic Brain Injury
Recruiting·—·Phase 3·NCT05323149·60 enrolled
Hyperbaric Oxygen Brain Injury Treatment Trial
Recruiting·—·Phase 2·NCT02407028·200 enrolled
Page 1 of 18

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)